Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007881 | 1.00 | SLC22A12 (0.44) | SLC22A12CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL2185411 | 0.89 | MAPK1 (0.41) | SLC22A12CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL2185414 | 0.88 | MAPK1 (0.42) | SLC22A12CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL2088936 | 0.87 | MAPK1 (0.42) | CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL1760794 | 0.86 | KMT2A (0.44) | CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL21205744 | 0.85 | KMT2A (0.43) | CYSLTR2CYSLTR1KMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL3447800 | 0.83 | MAPK1 (0.46) | SLC22A12CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL5035820 | 0.82 | L3MBTL1 (0.52) | SLC22A12KMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL1634164 | 0.82 | CYSLTR2 (0.59) | SLC22A12CYSLTR2CYSLTR1KMT2ASMN1; SMN2 | |
| SCHEMBL1634167 | 0.82 | CYSLTR2 (0.48) | SLC22A12CYSLTR2CYSLTR1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | claimed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| JP-4766693-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| US-7973052-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-07-05 | — | — | US | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| EP-1633340-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2010-11-10 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090156681-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-06-18 | — | — | US | claimed |
| EP-1633340-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-7514555-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-04-07 | — | — | US | claimed |
| EP-1633340-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2006-03-15 | — | — | EP | claimed |
| US-20060014784-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-01-19 | — | — | US | claimed |
| WO-2004091486-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-10-28 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-1633340-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060014784-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-01-19 | — | — | US | disclosed |
| WO-2004091486-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | SLC22A12 139/4885CYSLTR2 3271/4885CYSLTR1 2636/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | SLC22A12 257/4885CYSLTR2 1717/4885CYSLTR1 1528/4885 |
| US-20060014784-A1 | Compounds for the treatment of metabolic disorders | CPT1B, FABP1, CPT1A | SLC22A12 1588/4885CYSLTR2 4544/4885CYSLTR1 3975/4885 |
| US-20090156681-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, GPR119 | SLC22A12 1807/4885CYSLTR2 4494/4885CYSLTR1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.